Monopar Therapeutics (NASDAQ:MNPR) Given Overweight Rating at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a report released on Wednesday morning, Marketbeat.com reports. Piper Sandler currently has a $76.00 target price on the stock.

Separately, HC Wainwright lifted their price target on Monopar Therapeutics from $22.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, January 22nd.

Monopar Therapeutics Stock Performance

Shares of MNPR stock opened at $39.10 on Wednesday. Monopar Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $54.30. The firm has a market cap of $238.59 million, a P/E ratio of -19.85 and a beta of 1.18. The business’s 50 day moving average price is $36.46 and its 200-day moving average price is $22.11.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC bought a new stake in Monopar Therapeutics in the fourth quarter worth $23,435,000. Adage Capital Partners GP L.L.C. bought a new stake in Monopar Therapeutics in the fourth quarter worth $13,182,000. RA Capital Management L.P. bought a new stake in Monopar Therapeutics in the fourth quarter worth $11,247,000. Point72 Asset Management L.P. bought a new stake in Monopar Therapeutics in the fourth quarter worth $3,694,000. Finally, ADAR1 Capital Management LLC bought a new stake in Monopar Therapeutics in the fourth quarter worth $2,861,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.